Targeting SIRT1 activity in the AT as potential therapy, using nanocarriers with SIRT1- activating compounds, to dampen inflammation in patients exposed to increased risk of CHD, might be a promising research field. This evidence concerns the gene SIRT1 and coronary artery disorder.